[2] [2] DEO S S, SHARMA J, KUMAR S. GLOBOCAN 2020 report on global cancer burden: challenges and opportunities for surgical oncologists[J]. Ann Surg Oncol, 2022, 29(11): 6497-6500.

[3] [3] RAJPUT S, SHARMA P K, MALVIYA R. Biomarkers and treatment strategies for breast cancer recurrence[J]. Curr Drug Targets, 2023, 24(15): 1209-1220.

[4] [4] YAO Z T, YANG Y M, SUN M M, et al. New insights into the interplay between long non-coding RNAs and RNA-binding proteins in cancer[J]. Cancer Commun (Lond), 2022, 42(2): 117-140.

[5] [5] XIE J J, JIANG Y Y, JIANG Y, et al. Super-enhancer-driven long non-coding RNA LINC01503, regulated by TP63, is overexpressed and oncogenic in squamous cell carcinoma[J]. Gastroenterology, 2018, 154(8): 2137-2151. e1.

[6] [6] FENG J, GAO F Y, LI Y Y, et al. Upregulation of LINC01503 promotes cervical cancer progression by targeting the miR-615-3p/CCND1 axis[J]. J Cancer, 2021, 12(15): 4552-4560.

[9] [9] QU F L, WU S Y, LI J J, et al. Ipsilateral breast tumor recurrence after breast-conserving surgery: insights into biology and treatment[J]. Breast Cancer Res Treat, 2023, 202(2): 215-220.

[12] [12] AHMADPOUR S T, ORRE C, BERTEVELLO P S, et al. Breast cancer chemoresistance: insights into the regulatory role of lncRNA[J]. Int J Mol Sci, 2023, 24(21): 15897.

[13] [13] SHUAI Y, QIAN H, YUAN P. LINC01503 in cancer: from molecular mechanisms to therapeutic implications[J]. Clin Exp Med, 2024, 24(1): 120.

[15] [15] ZHANG M L, ZHAO T T, DU W W, et al. C-MYC-induced upregulation of LINC01503 promotes progression of non-small cell lung cancer[J]. Eur Rev Med Pharmacol Sci, 2020, 24(21): 11120-11127.

[17] [17] PENG X, GAO J, CAI C, et al. LncRNA LINC01503 aggravates the progression of cervical cancer through sponging miR-342-3p to mediate FXYD3 expression[J]. Biosci Rep, 2020, 40(6): BSR20193371.